Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.